Usman Baber to Mortality
This is a "connection" page, showing publications Usman Baber has written about Mortality.
Connection Strength
0.750
-
Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J. 2013 Aug; 166(2):373-380.e2.
Score: 0.429
-
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 12 02; 385(23):2150-2160.
Score: 0.047
-
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021 06 16; 373:n1332.
Score: 0.047
-
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
Score: 0.042
-
Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019 11 21; 381(21):2032-2042.
Score: 0.041
-
Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. Int J Cardiol. 2018 07 15; 263:24-28.
Score: 0.037
-
Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin)?±?Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention. Am J Cardiol. 2018 01 15; 121(2):168-176.
Score: 0.036
-
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
Score: 0.036
-
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
Score: 0.034